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Abstract
Objective—Determine whether prenatal depression interacts with autoimmune conditions to 
further increase the risk of preterm birth or preeclampsia.
Study design—Our sample included 3,034 pregnant women with rheumatoid arthritis (RA), 
Crohn’s disease (CD), psoriasis, or controls that were prospectively enrolled into MothertoBaby 
pregnancy studies. We estimated the independent and joint effects of the three autoimmune 
conditions and depression on the select outcomes.
Results—We found an increased risk of preterm birth among women with RA (2.10, 95% CI 
1.54, 2.87), CD (1.87, 95% CI 1.25, 2.81) or psoriasis (1.88, 95% CI 1.27, 2.79) independent of 
depression status. RA was also independently associated with preeclampsia. Prenatal depression 
was not independently associated with preterm birth or preeclampsia, nor was there any synergism 
with autoimmune conditions.
Conclusions—If these findings are confirmed, the absence of synergism should be encouraging 
news to the many women with select autoimmune conditions and depression in pregnancy.
Introduction
Autoimmune conditions are more prevalent in women than men, and often occur during a 
woman’s reproductive years.1 Generally, autoimmune conditions are not thought to 
substantially affect fertility,2 and thus many women and their clinicians are confronted with 
concerns about how autoimmune disease may affect pregnancy and birth outcomes. 
Autoimmune conditions have been associated with adverse birth outcomes, including 
preterm birth and preeclampsia;1 disease activity may increase these risks.3,4
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Depression, like many autoimmune conditions, is more prevalent in women and affects 
many during their reproductive years. According to the Centers for Disease Control, in the 
United States between 2009–2012, an estimated 9.3% of women ages 18–39 had moderate 
or severe depressive symptoms.5 Depression in pregnancy has also been associated with 
similar adverse birth outcomes as autoimmune conditions, including preterm birth and 
preeclampsia,6,7 although the findings are contradictory, and some have suggested that these 
associations result from medications taken for depression in pregnancy.8,9
As a result of the overlapping distributions of depression and autoimmune conditions in 
young women of reproductive age, it is not unexpected that they co-occur. Depression is a 
reported comorbidity of many autoimmune conditions,10–13 and has been associated with 
reduced quality of life11,14,15 in individuals with autoimmune disease. For example, patients 
with rheumatoid arthritis and comorbid depression have disproportionally worse 
functioning, decreased response to treatment, higher pain and increased disease activity.11 
Proposed mechanisms of the two exposures have been bidirectional, with depression 
affecting disease activity and vice versa through biological, psychological, and behavioral 
pathways.15
There is a dearth of literature examining these comorbidities in a pregnant population. Our 
group has reported that a disproportionate prevalence of comorbid depression and psoriasis 
persists in pregnancy;16 however, to our knowledge, there are no published reports on the 
effects of prenatal depression on birth outcomes in the offspring of women with autoimmune 
conditions. Given the commonalities in adverse birth outcomes from both autoimmune 
conditions and prenatal depression and the comorbidity of the exposures, it is critical that we 
investigate the potential synergism of these exposures on pregnancy and birth outcomes. 
Using a sample from a prospective cohort of women enrolled into MotherToBaby pregnancy 
studies, we hypothesized that: 1) women with rheumatoid arthritis (RA), Crohn’s disease 
(CD) and psoriasis have an increased risk of preeclampsia and preterm birth relative to 
controls; 2) prenatal depression independently predicts preeclampsia and preterm birth; 3) 
synergism results between the two exposures on the risk of preterm birth and preeclampsia.
Materials and Methods
Study sample
Subjects included in this analysis are a sample of 3,034 women enrolled into the 
MotherToBaby pregnancy studies between 2009–2015 that had a live birth. MotherToBaby, 
a service of the Organization of Teratology Information Specialists, provides evidence-based 
information about the risks of medications, chemicals, herbal products, illicit drugs, and 
diseases in pregnancy. MotherToBaby conducts prospective pregnancy studies to assess a 
spectrum of adverse pregnancy and birth outcomes in pregnancies exposed to diseases or 
therapeutic agents (including autoimmune diseases) relative to unexposed pregnancies. 
Details of study design and subject recruitment have been previously described.17 Briefly, 
subjects residing in the United States or Canada that speak English or Spanish are recruited 
through three primary mechanisms: 1) invitation to participate after calling the toll-free 
MotherToBaby telephone service; 2) direct-to-healthcare provider promotion for specific 
diseases, or 3) direct-to-consumer recruitment through the Internet/social media.
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MotherToBaby pregnancy studies were approved by the University of California, San Diego 
Institutional Review Board.
Study design and data collection
Upon enrollment in pregnancy, women are interviewed by telephone up to three times (any 
time before 20 weeks of gestation, 20–22 weeks of gestation, and 32–34 weeks of gestation, 
depending upon gestational age at enrollment). Women are queried about their family 
medical history, prescription and non-prescription medication exposures during pregnancy, 
tobacco use, previous pregnancy outcomes, and socioeconomic and demographic 
characteristics of the woman and her partner. The exposure history includes start and stop 
dates, dosage changes and frequencies for all medications, herbal supplements, vitamins, 
occupational exposures, and prenatal care testing or other procedures. Medical records are 
requested from OBGYNs and any specialty providers that managed the woman’s care in 
pregnancy. Self-reported exposures and diagnoses are confirmed by medical records when 
possible; discrepancies prompt further query of the woman.
Birth outcomes are obtained using a standard questionnaire conducted by telephone shortly 
after delivery. Women update exposure information, and report on birth outcomes, including 
live birth, stillbirth, elective termination, or spontaneous abortion, the presence or absence of 
major structural defects, gestational age at delivery, mode of delivery, infant Apgar scores, 
and infant birth weight, length, and head circumference. Additionally, medical records from 
the delivery hospital and pediatrician are requested for data abstraction and verification.
Exposures and outcomes
Subjects for this analysis were selected from the entire MotherToBaby database based upon 
self-report of one of the following: 1) RA; 2) CD; 3) psoriasis; or 4) no history of any of the 
following autoimmune diseases: RA, CD, psoriasis, psoriatic arthritis, lupus, ankylosing 
spondylitis, other autoimmune disease, antiphospholipid syndrome, celiac disease, 
connective tissue disease (mixed/undifferentiated), fibromyalgia, or ulcerative colitis 
(controls).
Depression was defined as a self-report of a diagnosis of depression that was not reported to 
be resolved, situational, or postpartum depression from a previous birth. Additionally, 
medications reported as taken by the mother in pregnancy and indicated for depression were 
categorized into trimester of use.
Preterm birth was defined as delivery prior to 37 weeks of gestation. Gestational age at 
delivery was based upon the self-reported last menstrual period of the mother and confirmed 
by medical records when possible. Discrepancies are resolved by ultrasound dating 
whenever possible. Preeclampsia was self-reported and verified with medical records when 
possible.
Statistical analysis
Frequencies and means were used to summarize all variables. Hypothesized causal models 
were created to identify confounders and potential selection biases for multivariable 
Bandoli and Chambers Page 3
J Perinatol. Author manuscript; available in PMC 2018 January 27.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
adjustment.18 We adjusted for race/ethnicity, socioeconomic status (measured using 
Hollingshead score19 based on occupation and education of the mother and her partner; 
dichotomized into high (>29) versus low (≤29)), medical comorbidities (high blood 
pressure, thyroid disorder and type-1 diabetes), pregnancy smoking, pre-pregnancy body 
mass index (BMI), maternal age at estimated due date, and gestational age at enrollment. To 
create propensity scores, we regressed each autoimmune condition on the potential 
confounders and outputted the probabilities to create propensity scores for adjustment. The 
computed probability of exposure (i.e.- probability of each autoimmune condition) was then 
included in the regression models as a continuous variable. The covariate for depression in 
pregnancy was omitted from propensity scores to estimate its independent effects with 
preterm birth and preeclampsia. Depression medication use was initially categorized into 
each of the three trimesters, but due to thin strata was collapsed into any antidepressant 
medication use during pregnancy.
Risk ratios for preterm birth were then estimated using logistic regression with a log link and 
a Poisson distribution. Models were first created with main effects of the autoimmune 
condition (RA, CD or psoriasis in separate models), depression and depression medications. 
However, due to the small sample of women taking depression medications, the covariate 
was dropped from models. Effects on the point estimates for autoimmune conditions and 
depression were minimal (<5%). Interaction terms for the autoimmune condition and 
depression were then included in each model to assess multiplicative joint effects. Separate 
models were constructed for RA, CD and psoriasis, and models were adjusted with 
propensity scores. Propensity score adjusted linear regression models were also created to 
estimate the average difference in the number of weeks of gestation associated with the 
autoimmune conditions. All analyses were then repeated to estimate the risk of 
preeclampsia. To assess additive interaction between autoimmune conditions and depression, 
we tested the relative excess risk due to interaction (RERI). By creating indicator variables 
for combinations of the autoimmune condition (yes/no) and depression (yes/no), parameter 
estimates and a covariance matrix were entered into a calculator (available at http://
www.epinet.se) assessing additive interactions.20 Finally, to assess effect measure 
modification by prenatal depression, logistic regression models for preterm birth and 
preeclampsia were stratified by prenatal depression status.
In sensitivity analyses, we excluded late enrollees (gestational age at enrollment >20 weeks). 
The data analysis for this paper was generated using SAS software, version 9.4 (Cary, NC, 
USA).
Results
In our final sample, 3,034 women had a singleton live birth. Of these, 1,703 had no 
diagnosis of an autoimmune disease as defined in the methods. For those with a single 
autoimmune diagnosis, 93% of those with RA, 72% with CD and 46% with psoriasis 
reported taking a medication for their autoimmune condition at some point during 
pregnancy.
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We found slightly elevated prevalence of self-reported depression in women with RA 
(11.0%) or CD (11.3%) compared to control subjects (8.9%). Women with psoriasis had 
twice the prevalence of depression (18.9%) compared to controls (p<0.0001).
Participants were majority non-Hispanic White, and approximately 50% were nulliparous at 
enrollment. Women with RA, CD or psoriasis were more likely to have a preterm birth. 
Women with psoriasis were more likely to report having depression than the other groups, 
although their frequency of depression medication use did not differ. Additionally, women 
with psoriasis tended to have higher pre-pregnancy BMI, report gestational diabetes in 
pregnancy, and smoke in pregnancy compared with the other three groups. Women with RA 
were more likely to report other medical comorbidities (high blood pressure, thyroid 
disorder or Type 1 diabetes), and they were less likely than the other groups to report 
additional psychiatric conditions (e.g. anxiety, schizophrenia) (Table 1).
Preterm birth
Women with RA, CD or psoriasis had increased risk of preterm birth compared to women 
with no autoimmune conditions (Table 2). In linear regression models, women with RA 
delivered on average 0.55 weeks earlier (95% CI −0.74, −0.36) compared to women without 
RA. Women with Crohn’s disease had average gestations reduced by 0.61 weeks (95% CI 
−0.85, −0.36) and women with psoriasis had gestations reduced by 0.30 weeks (95% CI 
−0.55, −0.05) compared to women without these autoimmune conditions (data not shown). 
Prenatal depression was not an independent risk factor for preterm birth in any of the 
models. There was no additive or multiplicative interaction between the autoimmune disease 
and depression in any models (p>0.10 in all models). There was indication of effect measure 
modification by prenatal depression on the effect estimate of psoriasis; women with prenatal 
depression had a stronger risk of preterm birth from psoriasis than women without prenatal 
depression, although confidence intervals overlapped.
Preeclampsia
When examining the risk of preeclampsia (Table 3), only RA was independently associated 
with preeclampsia. The effect estimates for CD and psoriasis were elevated but did not reach 
statistical significance. Again, there was no additive or multiplicative interaction between the 
autoimmune disease and depression in any models (p>0.10 in all models). There was also no 
evidence of effect measure modification by prenatal depression.
Sensitivity analyses
In sensitivity analyses restricted to the sample of women who enrolled prior to 20 weeks of 
gestational age, results did not change (data not shown).
Discussion
Our findings of an increased risk of preterm birth and preeclampsia from RA are similar to 
those of others. In a large population based cohort study of 1.9 million births in Denmark, 
offspring born to mothers with RA were almost 50% more likely to be born prematurely 
(RR 1.48, 95%CI 1.20, 1.84).21 Reed et al. reported a slightly higher risk of preterm birth 
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(RR 1.78, 95% CI 1.21, 2.60) in an analysis of birth records from Washington State between 
1987–2001.22 The same authors estimated a 55% increased risk of preeclampsia from RA 
(RR 1.55, 95% CI 0.97, 2.50), which was very similar to our findings. The increased risk of 
both outcomes in women with RA suggests that preeclampsia may be a mediator in the risk 
of preterm birth; future work may consider formal mediation analyses.
Our findings of an elevated risk of preterm birth from CD are also similar to previous 
studies. Using a cohort from the Swedish health registers including 470,110 singleton births, 
Broms et al. reported women with CD had higher odds of preterm birth than control women 
(OR, 1.65; 95% CI, 1.33–2.06).3 An earlier paper using medical birth registries in Sweden 
and Denmark found increased risk of moderately and very preterm birth (prevalence odds 
ratio [POR], 1.76; 95% CI, 1.51–2.05; and POR, 1.86; 95% CI, 1.38–2.52, respectively) 
from CD, but no increase in the risk of preeclampsia.23 Our effect estimates for CD and the 
risk of preeclampsia in the full sample were not statistically significant, although they were 
elevated and only slightly crossed the null. Additionally, in the stratum of women without 
depression, effect estimates were statistically significant (1.82, 95% CI 1.01, 3.30).
Finally, the evidence with regards to psoriasis and our select pregnancy outcomes is more 
limited and conflicting.24 Similar to our findings, Lima et al. found an increased odds for 
preterm birth/low birth weight composite (OR 2.02, 95% CI 1.19, 3.76) in women with 
psoriasis, but not for preeclampsia. However, an analysis of nationwide medical records 
from births in Taiwan found no increased risk for either outcome with psoriasis.25 Our effect 
estimate for the risk of preeclampsia from psoriasis was not statistically significant, although 
it was elevated and may lack power from the relatively small sample size. Similar to our 
findings with Crohn’s disease, our findings suggest that these autoimmune conditions may 
modestly increase the risk of preeclampsia, and should be considered in the care of pregnant 
women.
Overall, our risk estimates of preterm birth, while similar to previous estimates, were 
slightly stronger. This may be due to the selection of our sample compared with previous 
research. These select autoimmune conditions are generally rare, leading many to conduct 
research from population medical registries for sufficient sample size. In contrast, our cohort 
was comprised of women who, as a result of their disease, chose to participate in the study. 
This self-selection may result in a sample with higher disease severity and stronger risks for 
adverse pregnancy outcomes than large scale, record-based analyses.
When discussing our results, the limitations of our analyses should be considered. Non-
diseased women who volunteered for our studies may be healthier than the general 
population, as noted by the small proportions of control subjects who smoked in pregnancy 
or did not report prenatal vitamin use. With respect to our exposure and outcomes, the 
prevalence of depression (8.9%) and preeclampsia in our controls (3.5%) was similar to the 
United States (US) prevalence (9.3% in 2009–12, and 3.8% in 2010, respectively).5,26 
However, the prevalence of preterm births (5.9%) was much lower than that of the US 
(11.5% in 2012).27 This may have biased our autoimmune disease effect estimates for 
preterm birth away from the null. Also, although outside of the scope of this analysis, we did 
not address medication use for the autoimmune conditions or disease severity with the 
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outcomes, which may contribute to the risk estimates. Additionally, our sample of those with 
comorbid autoimmune conditions and depression was small, limiting our power to detect 
joint effects. Further, prenatal depression was self-reported with no measure of severity, 
although we would expect misclassification to be non-differential, potentially attenuating 
effect estimates. However, adding confidence to our estimates, 49% of women in our sample 
with self-reported depression were on an antidepressant medication during pregnancy, 
consistent with use in a general pregnant population.28 Finally, the indication of preterm 
birth (medically indicated, preterm premature rupture of the membranes, or spontaneous 
preterm birth) was not available at the time of data analysis. Investigation into whether the 
indication varied by autoimmune condition and its contribution to the observed increased 
risk is of preterm birth and should be considered in future research.
To our knowledge, this was the first study to assess the independent and joint effects of both 
autoimmune disease and depression on pregnancy outcomes. There is biologic rationale for 
our hypothesis of joint effects. It is hypothesized that systemic inflammation from the 
autoimmune condition contributes to the high level of depression, as depression itself is 
associated with an increase in inflammatory cytokines and acute-phase reactants.29 Birth 
outcomes such as preeclampsia30 and preterm birth31 have also been associated with 
inflammatory cytokines, leading us to hypothesize that women with both exposures have an 
even greater risk of these outcomes. Ultimately our data did not support this hypothesis, as 
maternal self-reported prenatal depression was not a risk factor for either preterm birth or 
preeclampsia in women with select autoimmune diagnoses. We did find potential effect 
measure modification by depression in the effects of psoriasis on preterm birth, as women 
with depression had a stronger risk of preterm birth from psoriasis than women without 
depression. However, confidence intervals were wide and overlapping, warranting further 
investigation. Maternal depression in this sample was not confirmed or classified by 
administration of symptom severity rating scales, likely resulting in a heterogeneous 
categorization of depression. Medications for depression, less likely to be as heterogeneous, 
had stronger effect estimates but very wide confidence intervals due to the small sample of 
exposed with the selected outcomes and were ultimately removed from models. Another 
interpretation of these results is that the strength of the associations of our select 
autoimmune conditions with preterm birth and preeclampsia make any comparison of risk 
from depression minimal. In a review of 47 studies of prenatal depression and preterm birth 
conducted since 1984, only 12 found statistically significant associations between 
depression and preterm birth, and effect measure ratios ranged from 1.3–4.9.7 Similarly, in 
analysis of pregnant women with untreated depression, antidepressant treated depression, or 
no depression, only those that took antidepressants in pregnancy had an increased risk of 
preeclampsia.8 Thus, while depression may operate on preterm birth and preeclampsia 
through similar inflammatory pathways as autoimmune diseases, the effects are likely 
weaker than those of RA, CD and psoriasis, and may not be measurably adding to the risk in 
these women.
This study adds to the literature by estimating the risks of preterm birth and preeclampsia 
from RA, CD and psoriasis. Further, we have expanded the study of autoimmune conditions 
in pregnancy by evaluating whether prenatal depression confers additional risk for preterm 
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birth or preeclampsia in women with our selected autoimmune conditions, which up until 
this point had not been reported.
In summary, women with RA, CD or psoriasis were more likely to have a preterm birth than 
control women. Self-reported depression in pregnancy was not associated with either of 
these outcomes. While our lack of independent or joint effects of prenatal depression may be 
welcome news to clinicians and women managing both exposures in pregnancy, subsequent 
studies should be performed utilizing larger datasets with more detailed depression 
information. Further research will complement our findings as we evaluate the important 
question of whether prenatal depression is indeed a modifiable risk factor for adverse 
pregnancy outcomes in women with select autoimmune conditions.
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Table 1
Pregnancy and sociodemographic characteristics of women enrolling in MotherToBaby pregnancy studies by 
autoimmune condition (n=3,034a).
Rheumatoid Arthritis
n=729
Crohn’s Disease
n=348
Psoriasis
n=330
Control
n=1703
Pregnancy and birth outcomes n (%) n (%) n (%) n (%)
Preterm birth (<37 weeks) 105 (14.4) 40 (11.5) 47 (14.2) 100 (5.9)
Preeclampsia 42 (5.8) 18 (5.2) 21 (6.4) 60 (3.5)
Maternal depression 80 (11.0) 41 (11.3) 58 (18.9) 153 (8.9)
 Depression medications in pregnancy 40 (50.0) 11 (26.8) 30 (51.7) 83 (54.2)
Medical comorbiditiesb 117 (16.1) 22 (7.3) 36 (10.9) 175 (10.3)
Other psychiatric condition 45 (6.2) 32 (9.2) 39 (11.8) 188 (11.0)
Gestational diabetes 58 (7.9) 24 (6.9) 33 (10.0) 91 (5.3)
Other maternal factors
Maternal age (mean, sd) 32.5 (4.8) 31.5 (4.4) 32.6 (4.8) 32.1 (5.1)
Gestational age at enrollment (mean, sd) 14.4 (7.7) 15.7 (8.8) 16.2 (8.4) 22.0 (9.2)
Gestational age at delivery (mean, sd) 38.6 (2.1) 38.6 (2.3) 38.7 (2.3) 39.3 (1.9)
Pre-pregnancy BMI (mean, sd) 25.0 (5.9) 24.6 (4.9) 26.9 (6.7) 24.7 (5.5)
Infant birth weight (kg) (mean, sd) 3.2 (0.6) 3.3 (0.6) 3.3 (0.6) 3.4 (0.5)
Socioeconomic status (low) 58 (8.0) 21 (6.0) 29 (9.0) 188 (11.0)
Nulliparity 348 (47.7) 206 (59.2) 169 (51.2) 877 (51.5)
Race/ethnicity
 non-Hispanic White 565 (77.5) 319 (91.7) 275 (83.3) 1240 (72.8)
 Hispanic 91 (12.5) 8 (2.3) 20 (6.1) 263 (15.4)
 African American 22 (3.0) 15 (4.3) 15 (4.6) 81 (4.8)
 Asian/other 51 (7.0) 6 (1.7) 20 (6.1) 119 (7.0)
Maternal pregnancy smoking 49 (6.7) 35 (10.1) 46 (18.1) 69 (4.1)
No prenatal or multivitamin use 1 (0.1) 1 (0.3) 1 (0.3) 5 (0.3)
a13 individuals with Crohn’s disease also have RA; 21 have psoriasis and RA; 36 have psoriasis and Crohn’s disease; 3 have all 3 conditions.
bincludes high blood pressure, thyroid disorder and Type 1 diabetes.
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